| 摘要 |
The present invention relates to a novel biomarker for diagnosing and treating triple-negative breast cancer and resistance to anti-hormone drug, and to a composition containing the same. More specifically, provided is a pharmaceutical composition which enables effective diagnosis of triple-negative breast cancer and resistance to anti-hormone drug, by measuring the expression rate of mRNA of a Mel-18 gene or a protein thereof. Furthermore, it is possible to remarkably improve therapeutic effects of hormone therapy in anti-hormone drug-resistant breast cancer including existing triple-negative breast cancer by increasing expression of the Mel-18 gene or injecting the Mel-18 protein. |
